2015
DOI: 10.1016/j.ejps.2014.11.012
|View full text |Cite
|
Sign up to set email alerts
|

Development of stabilized Paclitaxel nanocrystals: In-vitro and in-vivo efficacy studies

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

2
31
0

Year Published

2015
2015
2022
2022

Publication Types

Select...
6
1

Relationship

1
6

Authors

Journals

citations
Cited by 61 publications
(33 citation statements)
references
References 37 publications
2
31
0
Order By: Relevance
“…On the other hand almost similar z-average of nanocrystals was observed at stabilizer concentration 0.1% w/v (186.12±12.31nm) and 0.2% w/v (180.78±9.2nm) immediately after processing and this was in agreement to our previous report [21] where we found that once the stabilizer concentration is sufficient to cover the generated surface, further increase in stabilizer concentration did not affect the size reduction and PDI. Moreover, there was no significant change in particle size in these two formulations 1 hour after of formulation development [47].…”
Section: Preparation and Optimization Of Ptx/ncssupporting
confidence: 94%
See 2 more Smart Citations
“…On the other hand almost similar z-average of nanocrystals was observed at stabilizer concentration 0.1% w/v (186.12±12.31nm) and 0.2% w/v (180.78±9.2nm) immediately after processing and this was in agreement to our previous report [21] where we found that once the stabilizer concentration is sufficient to cover the generated surface, further increase in stabilizer concentration did not affect the size reduction and PDI. Moreover, there was no significant change in particle size in these two formulations 1 hour after of formulation development [47].…”
Section: Preparation and Optimization Of Ptx/ncssupporting
confidence: 94%
“…The results are shown in Fig.2 and as reported previously the mean particle size and PDI both decreased while the pressure increased from 1000 bars to 1800 bars [47]. The desired particle size range 150-225 nm was obtained at 1800 bars (10 cycles) and no further reduction in particle size was observed on increasing the number of cycles.…”
Section: Preparation and Optimization Of Ptx/ncssupporting
confidence: 73%
See 1 more Smart Citation
“…There is evidence that macrophages in atherosclerotic lesions express myeloperoxidase that yields a unique pattern of protein oxidation products. Myeloperoxidase is also pinpointed as a pathway that promotes LDL oxidation [7]. Natural products with antioxidant potential have been proposed as effective in the treatment of metabolic syndrome like insulin resistance, diabetes, obesity, altered lipid profile, and hypertension [8][9][10] The genus Crassocephalum is in the family Asteraceae (Compositae) in the major group Angiosperms (Flowering plants).…”
Section: Introductionmentioning
confidence: 99%
“…To increase solubility, the drug is mixed with Cremophor EL and alcohol under the trade names, Taxol® or Paxene®. Cremophor EL is a solvent for biological and pharmacological substances but has various side effects, such as hypersensitivity, nephrotoxicity, neurotoxicity and hyperlipidemia, as well as alters the pharmacokinetics of Paclitaxel® [4]. Therefore, the use of nanotechnology-based devices as Paclitaxel® carriers is recommended to enhance therapeutic efficacy and decrease the side effects of the drug [5].…”
Section: Introductionmentioning
confidence: 99%